Profound Medical Corp. 8-K

What Happened
Profound Medical Corp. (PROF) filed a Form 8-K on May 15, 2026 reporting the results of its shareholders’ meeting held May 13, 2026. Shareholders elected all eight director nominees to the Board, approved the appointment of PricewaterhouseCoopers LLP (PwC) as auditors through the next annual meeting, and approved an ordinary resolution concerning all unallocated restricted share units and deferred share units under the company’s long-term incentive plan (LTIP). The company’s management information circular describing these items was filed as Exhibit 99.1.

Key Details

• Meeting date: May 13, 2026; Form 8-K filed May 15, 2026.
• Directors elected (votes FOR and % FOR):
  • Arun Menawat: 12,773,374 (90.257%)
  • Brian Ellacott: 11,541,684 (81.554%)
  • Cynthia Lavoie: 11,586,793 (81.873%)
  • Murielle Lortie: 11,586,693 (81.872%)
  • Arthur Rosenthal: 11,180,113 (78.999%)
  • Frank Baylis: 12,945,473 (91.473%)
  • Thomas Wellner: 12,948,509 (91.495%)
  • Vafa Jamali: 12,885,003 (91.046%)
• Auditor appointment: PricewaterhouseCoopers LLP approved as auditors until the next annual meeting — 25,193,910 FOR (99.497%), 127,301 WITHHELD (0.503%).
• LTIP resolution: Approval of all unallocated restricted share units and deferred share units — 9,046,376 FOR (63.922%), 5,105,787 AGAINST (36.078%).

Why It Matters
Board composition, auditor selection, and LTIP approvals are governance items that affect oversight and executive compensation. Re-election of all eight nominees confirms the current Board slate; reappointing PwC ensures continuity of external audit oversight through the next annual meeting. Approval of the unallocated LTIP units clears the plan mechanics that could be used for future equity-based compensation, which may affect share dilution and management incentives. These are material corporate governance outcomes investors watch for assessing company direction and governance practices.